bullish
ACE910 (Emicizumab) – A Novel Factor VIII (FVIII) –Mimetic Bi-Specific Antibody
158 Views25 Jan 2017 15:18
ACE910 is yet another (first one being Rheumatoid Arthritis treatment Actemra) blockbuster potential late stage program that validates Chugai’s...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Chugai Pharmaceutical (4519 JP): Emicizumab Gets PDUFA Data27 Aug 2017
- ACE910 (Emicizumab) – A Novel Factor VIII (FVIII) –Mimetic Bi-Specific Antibody25 Jan 2017
x